Document is current
Any future updates will be listed below
-
Authors
Takagi, Masatoshi https://orcid.org/0000-0002-7580-9184
Ogawa, Chitose
Aoki-Nogami, Yuki
Iehara, Tomoko
Ishibashi, Eri
Imai, Minoru
Kihara, Tetsuro
Nobori, Kiyoshi
Hasebe, Kazuhisa
Mizutani, Shuki
Kimura, Toshimi
Nagata, Masashi
Yasuhara, Masato
Yoshimura, Kenichi
Yorozu, Pariko
Hosoi, Hajime
Koike, Ryuji
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP18lk0201048)
- License Information
-
More Information
Article History
Received: 23 October 2018
Accepted: 18 January 2019
First Online: 26 January 2019
Ethics approval and consent to participate
: This study was approved by the institutional review boards of each participating institution (Tokyo Medical and Dental University, National Cancer Center Hospital, and Kyoto Prefectural University of Medicine). Written, informed consent is to be obtained from patients and/or their representatives.
: Not applicable.
: The authors declare that they have no competing interests. Although AstraZeneca provided Olaparib as a gift, AstraZeneca does not play in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. All authors are not affiliated with AstraZeneca.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
